Digital Health Funding in H1 2025: Market Stabilizes, AI Dominates and Exits Return
Digital health funding held steady in the first half of 2025, with AI-focused startups capturing…
Digital Health Funding in H1 2025: Market Stabilizes, AI Dominates and Exits Return
Digital health funding held steady in the first half of 2025, with AI-focused startups capturing the majority of capital and driving rapid adoption among providers. The digital health space also saw two long-awaited IPOs as well as rising M&A activity, which are two signals of market maturity — but looming policy shifts may challenge long-term…
KalVista Drug Gets FDA Approval for Treating Acute Swelling Attacks From Rare Disease
KalVista Pharmaceuticals’ Ekterly is now FDA approved for treating acute swelling attacks from hereditary angioedema. The KalVista tablet provides an alternative to injectable or infused HAE medications from companies such as Takeda Pharmaceutical and CSL Behring. The post KalVista Drug Gets FDA Approval for Treating Acute Swelling Attacks From Rare Disease appeared first on MedCity…
Hospitals Are Investing in AI — How Can They Evaluate ROI?
AI doesn’t need to be a black box — and hospitals don’t need to invest based on blind faith. With the right structure, questions, and metrics in place, healthcare leaders can cut through the hype and make decisions that actually drive value. The post Hospitals Are Investing in AI — How Can They Evaluate ROI?…
Do orphan drugs deliver more survival gains per patient than non-orphan drugs?
Conventional wisdom holds that orphan drugs treat rare (by definition) and more severe diseases. Because they treat diseases with significant unmet needs, their health benefits per person are large. But are they really? Does conventional wisdom align with the evidence? To answer the question myself and colleagues at FTI Consulting, including co-author Marie Steele-Adjognon, conducted…
Breaking the Cycle: Unlocking the Untapped Opportunities in Healthcare Innovation
We’ve seen how transformative innovation can be when supported by focused investment. But if we want to continue advancing healthcare in meaningful ways, we must expand our lens and invest in the spaces that have been left behind. The post Breaking the Cycle: Unlocking the Untapped Opportunities in Healthcare Innovation appeared first on MedCity News.
The Secret To Improved Population Health Management May Be In Our Pockets
The rapid advances in AI and smartphone technologies hold promise for many stakeholders in the healthcare system — providers, payers, pharmaceutical drugmakers and public health agencies — that need to understand what’s happening with the patient in real time. The post The Secret To Improved Population Health Management May Be In Our Pockets appeared first on…
Debunked Episode 17: Is Big Pharma Prepared for Impact of Trump Administration’s Health Policies?
The Trump administration’s healthcare policy changes from the gutting of medical research grants to changes on the CDC vaccine board were the focus of the discussion on the latest episode of the Debunked Podcast with MedCity News Editor-in-Chief Arundhati Parmar and Samir Batra, managing partner of Health Innovation Pitch. The post Debunked Episode 17: Is…
A New Future for DNA
By KIM BELLARD As a DNA-based creature myself, I’m always fascinated by DNA’s remarkable capabilities. Not just all the ways that life has found to use it, but our ability to find new ways to take advantage of them. I’ve written about DNA as a storage medium, as a neural network, as a computer, in…
How Microsoft Is Sparking Innovation in Rural Hospitals
Rural hospitals are facing growing cybersecurity threats and digital demands but often lack the resources to respond — a gap Microsoft is working to close through discounted tools, free training and an AI innovation lab. The tech giant’s rural health initiative has reached more than 700 hospitals so far. The post How Microsoft Is Sparking…
Blockbuster Novartis Drug Fails Key Test Hoped to Expand Its Use to Rare Blood Vessel Disorder
Novartis’s Cosentyx failed to beat a placebo in a Phase 3 clinical trial in giant cell arteritis. The antibody drug was being developed as an alternative to Roche and AbbVie drugs whose approved uses include treating this autoimmune disorder affecting blood vessels. The post Blockbuster Novartis Drug Fails Key Test Hoped to Expand Its Use…
